April 25, 2018 / 12:08 PM / 7 months ago

BRIEF-Zogenix Announces Presentation Of New Efficacy And Safety Data From Its First Pivotal Phase 3 Clinical Trial Of ZX008 In Dravet Syndrome

April 25 (Reuters) - Zogenix Inc:

* ZOGENIX ANNOUNCES PRESENTATION OF NEW EFFICACY AND SAFETY DATA FROM ITS FIRST PIVOTAL PHASE 3 CLINICAL TRIAL OF ZX008 IN DRAVET SYNDROME

* ZOGENIX - PATIENTS ON ZX008 ACHIEVED SIGNIFICANT, CLINICALLY MEANINGFUL REDUCTION IN TOTAL SEIZURE FREQUENCY COMPARED TO THOSE ON PLACEBO Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below